Skip to main content

SCDAA_2026_Convention_Program

Page 1

SICKLE CELL DISEASE ASSOCIATION OF AMERICA, INC. ®

HOPE

54TH ANNUAL NATIONAL CONVENTION

AN ERA OF HEALING, OPTIMISM, PERSEVERANCE AND EXCELLENCE

OCTOBER 15-17, 2026 Embassy Suites by Hilton Charlotte Concord Golf Resort & Spa Concord, North Carolina

LEGACY SPONSOR


B:8.75" T:8.5" S:8.25"

Legacy Sponsor

Standing with the sickle cell community

Pfizer remains committed to and engaged with the sickle cell community through ongoing connection, listening, learning, and research efforts. Scan the QR code to connect with Patient Affairs Liaisons (PALs) or visit pfizersicklecellcommitment.com

PP-LTV-USA-3565 ©2026 Pfizer Inc. All rights reserved. September 2026

2|

T:11"

S:10.75"

Sickle cell ambassadors pictured left to right: Ife and Demeatrice, caregivers; Maurice, Makenzie, and Markus, sickle cell warriors.


TABLE OF CONTENTS ® National Staff ..........................................................................................................4

Patient Empowerment Symposium........................................................35

President’s Greeting...........................................................................................5

SCDAA Masterclass Part Two.....................................................................36

Chief Medical Officer’s Greeting..................................................................6

Awards......................................................................................................................38

SCDAA Board of Directors................................................................................8

SCD C.A.R.E.S. Consortium Members..................................................... 42

Corporate Advisory Council...........................................................................9

SCDAA Members................................................................................................43

MARAC Members................................................................................................10

Our Sponsors........................................................................................................48

Abstract Reviewers/Convention Committee..................................... 12

Ways to Give.........................................................................................................50

Who We Are............................................................................................................ 13 Externally-Led Patient Focused Drug Development Meeting.....15 National Highlights............................................................................................16 SCDAA Member Leadership Intensive.................................................. 23 Honor Lectures................................................................................................... 24 Advocacy Update............................................................................................... 32 Summit on Stem Cell Transplant and Cellular Therapies..........34

FOLLOW US! @scdaa

@SCDAAorg

facebook.com/ sicklecellcampaign

linkedin.com/ company/scdaa-national

Privacy & Proprietary Information Notice: Please be aware that livestreaming, filming, videotaping, recording, reproducing or copying convention sessions in any format is prohibited. |3


®

NATIONAL STAFF OUR MISSION Regina Hartfield President and Chief Executive Officer

Reginald Hart, Jr. Chief Financial Officer

Erika Cartledge Director of Development and Stakeholder Engagement

To advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.

Kevin Amado, MPA Senior Community Impact and Education Manager

Natasha Thomas Events and Special Projects Manager

Joel Nepomuceno Membership Engagement Manager

PUBLISHER:

Sickle Cell Disease Association of America, Inc. EDITOR AND GRAPHIC DESIGN:

Bonnie Heneson Communications, Inc.

Teaira Brown Staff Accountant

Phoelicia Blagmon Executive Assistant

4|

7240 Parkway Drive, Suite 180 Hanover, MD 21076 410.528.1555 (office) | 410.528.1495 (fax) info@sicklecelldisease.org | sicklecelldisease.org


PRESIDENT’S GREETING DEAR FRIEND: It is my pleasure to warmly welcome you to the Sickle Cell Disease Association of America, Inc. (SCDAA) 54th Annual National Convention. We are excited to be here with you at the Embassy Suites by Hilton, Charlotte Concord Golf Resort & Spa in Concord, North Carolina. Our theme this year is HOPE: An Era of Healing, Optimism, Perseverance and Excellence, inspired by North Carolina’s iconic state flower, the dogwood. A symbol of hope and new beginnings, it is a clear reflection of the unbreakable spirit of our community as we enter a new era of sickle cell care. Recent advances in sickle cell treatment and changes to federal policies have cast a new light on the totality of sickle cell disease. The true impact isn’t just found in the physical toll of sickle cell; it’s found in unplanned days off work and missed birthday parties. It’s found in time spent deciphering Medicaid policy changes and researching clinical trials. We can’t forget the emotional impact surrounding the disease and the overwhelming stigma that often comes with it. It’s found in internal debates about whether the pain is severe enough to go to the hospital, and now, with more and more people successfully completing gene therapy, it’s found in the uncertainty that can come with a new beginning.

Our programming this year speaks to these topics and many more with HOPE. Whether you are an individual living with SCD, a caregiver, a researcher, a healthcare provider, an advocate or have another connection, we hope this year’s convention gives you new tools to utilize and widens your perspective on what it means to live with sickle cell disease. Most important, we hope this year’s convention fills you with HOPE. For the second time, we are excited to host our member organizations during the SCDAA Leadership Intensive on Wednesday, October 14. These three sessions will cover important subjects and help build our collective capacity.

Regina Hartfield President and CEO Sickle Cell Disease Association of America, Inc.

Don’t forget to join us on Friday to celebrate the brilliance among us during the SCDAA Gala: Rare and Radiant. Put on your dancing shoes and dazzle us with jewel-toned formal wear. Together, we’ll create a gorgeous sea of bold colors highlighting the beauty and strength of our sickle cell community. Welcome to all and thank you so much for being here. HOPE is easier to find and hold onto when we are all together.

|5


CHIEF MEDICAL OFFICER’S GREETING DEAR FRIEND: Thank you for attending the SCDAA 54th Annual National Convention. This year’s theme of HOPE helps to levelset where we are as a community and what we need to do to ensure a better future for individuals with sickle cell disease. We are in a new era. When I was born with SCD, hemoglobin SS in the early 1970s, the average life expectancy in the USA was 14 years. Warriors would experience complications that would lead to premature deaths. Advances such as newborn screening, penicillin prophylaxis, transcranial doppler and hydroxyurea have allowed the sickle cell community to identify and treat these complications. Today, there is much more hope, with well over 90% of those born with SCD living into adulthood and the average life expectancy in the USA being 53. We also have many reasons to be optimistic about the future. In the 1990s, I participated in an SCD drug trial. The drug was so effective in the treatment of SCD that the FDA ended the study early, and hydroxyurea was approved. It would take nearly 20 more years before another SCD therapy, Endari, would be approved by the FDA. While there have been ups and downs in SCD treatment since 2017, including an FDA approved therapy being taken off the market, there have also been successes, including the new cell and gene therapies being made available for 6|

the SCD community with assistance from the Centers for Medicare and Medicaid Services (CMS) Cell and Gene Therapy Access Model. There are more therapies for SCD approved by the FDA and in the pipeline than ever before. If the past year has shown our community anything, it is that we must persevere to continue the movement toward better care and a cure for all sickle cell patients. This year has presented significant public policy challenges to the community. We have seen the defunding and dismantling of programs that have helped gather SCD data. There are changes to the Health Resources and Services Administration (HRSA) sickle cell programs and uncertainty around the Sickle Cell Disease Newborn Screening Program. We anticipate that these changes will directly impact the ability of SCDAA communitybased organizations to support the communities they serve. We also expect that there will be significant challenges for individuals with SCD who rely on Medicaid when changes to state Medicaid programs are implemented in 2027. The SCDAA, along with our partners, recognize that it is time to dig deep and preserve our efforts to grow and continue to be a resource for the sickle cell community. This will take innovating and exploring different strategies to secure funding, finding new partners and learning more effective ways of doing things, but if we stand together, we can achieve this. By having hope, being optimistic and persevering through these challenges, we can create an environment where excellence in SCD care is not only promised but delivered.

Edward Donnell Ivy, MD, MPH Chief Medical Officer Sickle Cell Disease Association of America, Inc.


Sickle Cell Disease Association of America, Inc.

® Invites you to Join us for the scdaa gala

RARE & RADIANT An Evening Celebrating the Brilliance Among Us Friday, October 16 Cocktail reception 6:30 p.m. Gala 7:30 p.m. Concord Ballroom Embassy Suites by Hilton Charlotte Concord Golf Resort & Spa Dress your opulent Jewel-toned elegant best! Join us for a fun-filled evening of dinner and dancing. When all of us are gathered together, standing tall in jewel tones, it’s going to be a gorgeous sea of bold colors highlighting our beautiful and strong sickle cell community.

Legacy Sponsor

|7


MEET OUR BOARD OF DIRECTORS

Thomas L. Johnson, JD Chair of the Board Executive Director ASAP 340B Washington, DC

Adeyinka Ogunlegan, Esq. Vice Chair Chief of Staff and Vice President, Federal Affairs National Urban League Washington, DC

Ed Flowers Board Secretary Managing Partner and CHRO Practice Leader and Executive Committee Member DHR Global Atlanta, GA

Kenneth Thorpe, PhD, MA Board Treasurer Robert W. Woodruff Professor and Chair, Department of Health Policy and Management Rollins School of Public Health Emory University Atlanta, GA

Edward Donnell Ivy, MD, MPH Chief Medical Officer Education Coordinator Sickle Cell Awareness Group of Ontario Toronto, ON

Crawford J. Strunk, MD Vice Chief Medical Officer Co-Director, Sickle Cell Medical Neighborhood Cleveland Clinic Cleveland, OH

Krystal Folk-Nagua, DSW Senior Director of Programs Girls for Gender Equity Brooklyn, NY

TaLana Hill-Hughes, MPH Executive Director Sickle Cell Disease Association of Illinois Chicago, IL

Christopher Hollins, MBA Executive Vice President Strategic Acquiring Partnerships WorldPay, Inc. Atlanta, GA

Lewis Hsu, MD, PhD Director, Pediatric Sickle Cell Center and Professor of Pediatrics Pediatric Hematologist University of Illinois at Chicago Chicago, IL

Katherine Napier, EDB, CPA, MBA, CISA, CIA Senior Vice President for _ Finance/Chief Financial Officer Morehouse School of Medicine Atlanta, GA

Akua Okunseinde, MBA Co-Founder and Chief Growth Officer Karité Haworth, NJ

8|


MEET OUR BOARD OF DIRECTORS

Crystal A. Riley, PharmD, MHA, MBA Deputy Director/Government Policy Baxter International, Inc. Washington, DC

JaKela Walker Head of Finance, North America dsm-firmenich Princeton, NJ

Kim Smith-Whitley, MD CMAO RWE, Patient Advocacy and External Collaboration Pfizer San Francisco, CA

EMERITUS

Georges C. Benjamin, MD Chief Executive Officer American Public Health Association Washington, DC

Wayne A. I. Frederick, MD, MBA Interim President, President Emeritus, Charles R. Drew Professor of Surgery Howard University Washington, DC

CORPORATE ADVISORY COUNCIL Biree Andemariam, MD University of Connecticut School of Medicine Founding Director, New England Sickle Cell Institute (NESCI) Director, Connecticut Bleeding Disorders Center Tanesha Johnson, PhD Assistant Professor University of Kentucky A. Kyle Mack, MD Medical Principal Cigna Healthcare

Carol McFarland Director of Development, University Strategic Initiatives Howard University Genice T. Nelson, DNP, APRN, ANP-BC Program Director, New England Sickle Cell Institute and Connecticut Bleeding Disorders Programs UConn Health

Chris Ruffin, Jr. Executive Producer WJXT News 4 Jacksonville Bobby Staten III Bobby Staten + Co.

|9


Medical and Research Advisory

COMMITTEE MEMBERS (MARAC) Miguel R. Abboud, MD, PhD Professor of Pediatrics and Pediatric Hematology-Oncology Chairman Department of Pediatrics and Adolescent Medicine American University of Beirut, Lebanon Melissa Creary, PhD, MPH Assistant Professor, Health Management and Policy School of Public Health University of Michigan Ann Arbor, Michigan Lori Crosby, PsyD Co-Director, Innovations in Community Research, Division of Behavioral Medicine and Clinical Psychology Co-Director, CCTST, Community Engagement Core Psychologist, Research, Behavioral Medicine and Clinical Psychologist Cincinnati Children’s Professor, UC Department of Pediatrics Cincinnati, Ohio James Eckman, MD Professor Emeritus Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, Georgia

10 |

Lewis Hsu, MD, PhD Former Chair, Medical and Research Advisory Committee, Sickle Cell Disease Association of America, Inc. Director, Pediatric Sickle Cell Center Professor of Pediatric Hematology-Oncology University of Illinois Chicago Chicago, Illinois Edward Donnell Ivy, MD, MPH Chief Medical Officer, Sickle Cell Disease Association of America, Inc. Chair, Medical and Research Advisory Committee, Sickle Cell Disease Association of America, Inc. Education Coordinator Sickle Cell Awareness Group of Ontario Toronto, Ontario Elizabeth Klings, MD Associate Professor of Medicine Director, Center for Excellence in Sickle Cell Disease Director, Pulmonary Hypertension Center Boston University School of Medicine Boston, Massachusetts Lakshmanan Krishnamurti, MD Professor of Pediatrics Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant Yale University New Haven, Connecticut


HOPE Sophie Lanzkron, MD Professor of Medicine Division Director of Hematology Thomas Jefferson University Philadelphia, Pennsylvania Julie Makani, FRCP, PhD Associate Professor Department of Haematology and Blood Transfusion Muhimbili University of Health and Allied Sciences Dar es Salaam, Tanzania Caterina P. Minniti, MD Consulting Hematologist Former Director, Sickle Cell Center Montefiore Health System Bronx, New York

Crawford J. Strunk, MD Vice Chief Medical Officer, Sickle Cell Disease Association of America, Inc. Co-Director, Sickle Cell Medical Neighborhood Cleveland Clinic Cleveland, Ohio Julie Kanter-Washko, MD Associate Professor, Division of Hematology Oncology Director, Adult Sickle Cell Clinic University of Alabama at Birmingham Birmingham, Alabama Wanda Whitten-Shurney, MD CEO and Medical Director Sickle Cell Disease Association of America, Michigan Chapter, Inc. Detroit, Michigan

Genice T. Nelson, DNP, APRN, ANP-BC Corporate Advisory Council Member, Sickle Cell Disease Association of America, Inc. Program Director, New England Sickle Cell Institute and Connecticut Bleeding Disorders Programs UConn Health Farmington, Connecticut

| 11


THANK YOU ®

ABSTRACT REVIEWERS The Sickle Cell Disease Association of America, Inc., thanks everyone who reviewed this year’s research paper abstract submissions: Ofelia Alvarez, MD Biree Andemariam, MD Nina Anderson, DNP, RN, FNP-BC Rae Blaylark Andrew Campbell, MD Sonali Chaudry, MD Lori Crosby, PsyD Deepika Darbari, MD

Laura DeCastro, MD

Shannon Phillips, RN, PhD

James Eckman, MD

Jerlym Porter, PhD, MPH

Victor Gordeuk, MD

Annie Ross-Womack

Nancy Green, MD

Santosh Saraf, MD

Kisha Hampton, MPH

Kay Saving, MD

André Marcel Harris, MSW

La’Shardae Scott, DSW, MSW, CHES, CHW

Tokara Henry

Sruti Shiva, PhD

Lewis Hsu, MD, PhD

Lisa Shook, SHPE, MA, MCHES, CCP

TaLana Hughes, MPH

Wally R. Smith, MD

Edward Donnell Ivy, MD, MPH

Crawford J. Strunk, MD

Sara Jacobs, MD

Paula Tanabe, RN, PhD

Elizabeth Klings, MD

Alexis Thompson, MD, MPH

Gabrielle Lapping-Carr, MD

Wanda Whitten-Shurney, MD

Punam Malik, MD

Gentry Wilkerson, MD

Genice Nelson, DNP, APRN, ANP-BC

Katherine Wood, PhD

Foluso “Joy” Ogunsile, MD

CONVENTION PLANNING COMMITTEE SCDAA thanks the members of the Convention Planning Committee for the many hours they spent and the commitment they made to bring this wonderful event to fruition.

Regina Hartfield TaLana Hughes, MPH Baba Inusa, MD

CONVENTION PLANNING COMMITTEE CHAIRS

Edward Donnell Ivy, MD, MPH Genice Nelson, DNP, APRN, ANP-BC

Kim Smith-Whitley, MD

Miguel R. Abboud, MD, PhD

Wanda Whitten-Shurney, MD

Crawford J. Strunk, MD

Mary LaMar Bentley

Natasha Thomas

Raffaella Colombatti, MD, PhD

Annie Ross-Womack

Krystal Folk-Nagua, DSW, MSW, BSW 12 |

Reginald Hart, Jr.


WE SERVE as the national voice

for SCD working to resolve issues surrounding sickle cell disease and sickle cell trait. Since 1972, the organization has been on the forefront of improving the quality of health, life and services for individuals, families and communities affected by this rare disease and related conditions.

WE PROMOTE the search for a

universal cure for all people in the world with sickle cell disease.

WE JOIN with our 50+ member

organizations across 31 states to collectively serve over 500,000 children and adults living with or impacted by sickle cell disease and their families and caregivers.

THIS IS WHO WE ARE M O R E I M P O R TA N T LY THIS IS WHAT WE DO

WE CONNECT SCD warriors to our Clinical Trial Finder — a centralized, simple-to-navigate website to help people with sickle cell disease, their families and caregivers find clinical trials: sicklecelldisease.org/clinical-trial-finder.

WE TRAIN hundreds of Community Health Workers (CHWs) across the nation to assist families, helping to manage their health care strategy and access to care.

WE ADVISE on current medical news affecting you through SCDAA’s Medical and Research Advisory Committee (MARAC). The committee, comprised of world-renowned SCD experts, provides vital disease, clinical trial and therapy updates as they happen.

WE LEAD by building leadership skills. The Leadership Academy helps community-based organizations and SCD professionals become even more productive, with capacity building and up-to-date information.

WE EDUCATE throughout the year by holding our Masterclass Series as well as our Annual

National Convention to foster the exchange of the latest scientific and clinical information through innovative training seminars and educational workshops, interactive panel discussions, advocacy lectures and special events.

WE ADVOCATE so SCD warriors and families know they are not alone. Together with our member organizations, we have created a strong network that includes caregivers, clinicians, stakeholders and experts.

WE PARTNER together with organizations to improve lives, make change and show that #SickleCellMatters.

sicklecelldisease.org | 13


MEET THE VERTEX PATIENT EDUCATORS OUR COMMITMENT Vertex Patient Educators are committed to providing education about sickle cell disease (SCD) to help empower people living with this condition to have meaningful conversations with their healthcare providers. Visit our booth to: Connect with the Patient Educators and other members of your community Learn more about sickle cell disease and gene therapy Get helpful tips for talking to your healthcare provider Vertex Patient Educators are not able to provide medical advice. A patient’s healthcare team is always the primary source for information related to their health and treatment.

Visit our booth and learn more about what we do at VertexEducators.com.

Vertex and the Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated. Vertex Patient Educators is a trademark of Vertex Pharmaceuticals Incorporated. © 2026 Vertex Pharmaceuticals Incorporated l VXR-US-02-2500578 (v3.0) l 09/2026

14 |

Follow us: @vertexeducators


B

C Save the Date

SICKLE CELL DISEASE

VOICE S SHAPING CHANGE

An Externally Led Patient-Focused Drug Development Meeting for Sickle Cell Disease

January 27, 2027 | Virtual | 11 a.m.-3 p.m., EST The Sickle Cell Voices Alliance, a partnership among the Sickle Cell Disease Association of America, Inc., Sickle Cell Disease Association of Canada and Sickle Cell Society (UK), is hosting an externally led patient-focused drug development (EL-PFDD) meeting.

F

SCD

This virtual forum brings together national and global sickle cell patient and caregiver voices to ensure early involvement in drug development and encourage the FDA and key stakeholders, including other regulatory authorities, to consider a broader range of clinically meaningful endpoints when evaluating therapies for SCD.

SCD

VOIC S

What Are Externally Led Patient-Focused Drug Development (EL-PFDD) Meetings?

V

SHA CHA

Externally led patient-focused drug development meetings give the U.S. Food and Drug Administration (FDA) and other key stakeholders, including medical product developers, healthcare providers and federal partners, an important opportunity to hear directly from patients, their families, caregivers and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform decisions and oversight both during drug development and during review of a marketing application.

SHAPING CHANGE

For more information, visit sicklecelldisease.org/ELPFDD2027 or email ELPFDD2027@sicklecelldisease.org.

SICK

®

LE

C

H EL

IS L D

EASE

S CD

I Hosted by the Sickle Cell Voices Alliance, a partnership among the Sickle Cell Disease Association of America, Inc., Sickle Cell Disease Association of Canada and Sickle Cell Society (UK).

SICKLE CE | 15


NATIONAL HIGHLIGHTS A

A YEAR IN REVIEW

SPECIALIZED PROGRAMMING The Sickle Cell Disease Masterclass Now in its third year of programming, SCDAA was proud to continue to bring important conversations to the forefront with our masterclass series. The livestreamed series helps sickle cell disease warriors, caregivers, providers and others understand new perspectives on SCD and its treatment. Masterclasses are sponsored by Pfizer and Novo Nordisk. Sessions included:

Wellness During the Holidays and Other Special Occasions: Tips for Navigating Your Emotional Wealth and Well-Being During this December 2025 session, experts provided those living with SCD and their caregivers guidance on navigating holidays and special occasions which can often bring feelings of loss, grief and stress. Our panel provided participants with tools and tips to pave the way to acceptance, wellness and joy. Chronic or Acute? Rethinking the Approach to Sickle Cell Disease Care In this two-part series, our Masterclass panel of experts and warriors explored how new approaches to sickle cell disease care can help improve outcomes and shape how healthcare is addressed now and in the future. Part one was held during National Sickle Cell Awareness Month. Join us for part two during the annual convention!

SCDAA LAUNCHES NEW WEBSITE SCDAA was excited to start the new year with a new website. Visit sicklecelldisease.org and check out the redesign and updates that included: • New SCDAA member organization finder designed to help you quickly identify your closest member organization. • Updated resources for warriors/caregivers and providers. • New information on sickle cell disease, sickle cell trait and the differences between the two. • Enhanced Clinical Trial Finder with a hover glossary enabled, helping you to better understand your search results. 16 |

• E xpanded history section, where you can learn about the origins of SCDAA and the major events that have brought us where we are today.


NATIONAL HIGHLIGHTS ADVOCACY On the Hill This year, our annual Advocacy Days events were crucially important amid the many changes at the federal level to sickle cell disease funding and programs. In May, 24 representatives from 13 SCDAA member organizations across 11 states traveled to Washington, DC, to meet with members of Congress and their staff regarding issues impacting the SCD community. This year’s meetings focused on protecting the Sickle Cell Disease Newborn Screening Follow-Up Program by asking Members of Congress to sign a Congressional letter to Secretary Kennedy and HRSA Administrator Engels requesting that the grants for the program be extended. The sign-on letter closed with 27 total signers, reflecting a huge showing of support from members of Congress on this important issue. Member organization representatives also encouraged legislators to cosponsor the Sickle Cell Disease Comprehensive Care Act (H.R. 5178 or S. 721) to help improve clinical and cost-effective care for Medicaid beneficiaries with SCD and compelled members of Congress to join the recently relaunched bipartisan Sickle Cell Disease Caucus. Two new members — Reps. Mfume (D-MD) and Doggett (D-TX) — joined the caucus as a result of SCDAA’s work on the Hill!

ADVOCACY DAYS BY THE NUMBERS Representatives from 13 SCDAA Member Organizations across 11 states attended 34 meetings on Capitol Hill

27 members of Congress signed a letter requesting protection for the Sickle Cell Disease Newborn Screening Follow-Up Program

Two new members joined the bipartisan Sickle Cell Disease Caucus

| 17


NATIONAL HIGHLIGHTS HHS Office of Minority Health Sickle Cell Disease Webinars In May and June, Dr. Edward Donnell Ivy, SCDAA’s chief medical officer, joined the Department of Health and Human Services Office of Minority Health for a two-part roundtable webinar series focused on advancing comprehensive systems of care for sickle cell disease. Participants learned about and discussed key components of comprehensive SCD care, current challenges and emerging best and promising practices. Preparing for Medicaid Changes SCDAA created resources to help support individuals with SCD and their caregivers navigate changes to Medicaid eligibility, enrollment processes and more. The changes, which go into effect on January 1, 2027, indicate that states must require applicable individuals to demonstrate work reporting requirements as a condition of eligibility for Medicaid at application and renewal. SCDAA’s Preparing for Medicaid Changes document outlines steps that can be taken today to protect coverage.

Preparing for Medicaid Changes On July 4, 2025, President Trump signed into law a bill that cuts $1 trillion from the Medicaid program and makes sweeping changes to eligibility, enrollment processes and more. The new requirements don’t go into effect immediately – but we know they are coming. Here are some steps you can take to protect your Medicaid coverage now and, in the future, as the new requirements go into effect.

Know the name of your Medicaid program (some go by names like HuskyHealth, BadgerCare, Apple Health; some programs are managed by insurers like Aetna or Centene). Visit Medicaid.gov or your state’s medicaid agency website.

Make sure that your contact information is up to date with your Medicaid program, and make a practice of logging into your Medicaid account regularly to check for updates.

Sign up for access to your state’s Medicaid portal (if applicable). Check this portal often for messages.

Consider having a trusted family member or friend be your “Medicaid Buddy” to help you keep track of due dates, assist with application completion, remind you of enrollment periods or even attend Medicaid appointments.

Be sure to open all mail and emails from Medicaid and/or your state’s health department and your insurer. If you receive any communication, respond within the deadline (typically 10-30 days).

Begin keeping detailed records of your monthly work or qualifying activities (e.g., caregiving, school, community service). These can include pay stubs, schedules, attendance sheets, etc.

EVENTS

sicklecelldisease.org

SCDAA encourages you to connect with your local sickle cell CBO/SCDAA Member Organization for assistance with completing the above and check the SCDAA website for further information and/or resources.

FEBRUARY: Rare Disease Day Again this year, SCDAA joined the global rare disease community in spreading awareness and understanding. The annual fundraiser was a success and helped strengthen the work that supports the sickle cell community all year.

JUNE World Sickle Cell Day and Sickletini Happy Hour SCDAA supported the Global Alliance of Sickle Cell Disease Organizations (GASCDO) and Cayenne Wellness Center in highlighting the 2026 theme “Closing the Survival Gap: Equity in Sickle Cell Disease.” In recognition of World Sickle Cell Day, SCDAA hosted a virtual Sickletini Happy Hour on June 16. Warriors, caregivers and advocates from around the world joined us for a fun evening of education and connection, including games, drink demonstrations and a panel discussion on the topic “Sickle Cell Is a Disease, Not a People.”

Research That Heals: Partnering With Patients to Transform SCD Care SCDAA partnered with the National Heart, Lung, and Blood Institute (NHLBI) for this community forum, held in June in Maryland, and virtually. The free forum was a crucial platform for engaging directly with the sickle cell disease (SCD) community, including individuals with SCD and their caregivers, healthcare providers and community-based organizations. During the forum, participants discussed and developed solutions to enhance care and improve the quality of life for children and adults living with sickle cell disease.

18 |

®


NATIONAL HIGHLIGHTS JULY SCDAA Warrior Walkathon While the extremely poor air quality and code purple in Baltimore, Maryland, on the day of the walk prevented us from holding this annual event in person, we thank the many supporters and sponsors who raised funds to support our mission. We look forward to walking with you next year!

Jack and Jill of America Community Health & Resource Fair On July 25, SCDAA was proud to join Jack and Jill of America, Inc., at their Community Health & Resource Fair in Baltimore. Thank you for inviting SCDAA to connect with the community, share educational materials and raise sickle cell awareness.

SEPTEMBER: Celebrating Sickle Cell Awareness Month You Look Fine Documentary Screening On September 3, members of the SCDAA national team attended the Maryland showing of “You Look Fine,” a new documentary by comedian, warrior and filmmaker J. Snow. We were honored to join others in the sickle cell community for this night of reflection and conversation. Sickle Cell Awareness Night at Camden Yards September 9 was a night full of SCD awareness and Orioles baseball in Baltimore. During this special event, SCDAA shared resources with attendees at our booth, cheered on sickle cell warrior Cimone Vaughn as she threw the ceremonial first pitch and stepped onto the diamond to accept a generous donation from the Orioles. The Maryland Sickle Cell Disease Association, an SCDAA member organization, and the Central Maryland Chapter of the American Red Cross of the National Capital & Greater Chesapeake Region also benefitted from a portion of the ticket sales. Thank you to the Orioles for hosting this exceptional evening and for your support of SCDAA!

| 19


NATIONAL HIGHLIGHTS 2nd Annual Golf Classic We are thrilled to announce that the 2nd Annual SCDAA Golf Classic was a hole-in-one success, raising $17,000 to help fuel awareness, advocacy and support for individuals living with sickle cell disease. Thank you to our golfers, sponsors, the Chapel Hills Golf Club in Douglasville, Georgia, and everyone who joined us for this fun day of sport and community on the green.

SCDAA

GOLF . D CLASSIC m S . C u E i . t S

SCD C.A.R.E.S. CONSORTIUM

r R . o A s . C Con

Through their work, the SCD C.A.R.E.S. (Collaboration of Advocates for Research, Education and Science) Consortium continued to educate about and bring awareness to the importance of clinical trials. • A new glossary functionality was enabled on the Clinical Trial Finder to increase participants’ understanding of relevant terms. A user can now hover over an unfamiliar word to quickly see its definition. • Clinical trial users can now search in both English and Spanish. SCD • We continued to share stories and information about the crucial role clinical trials play in advancing Collaboration of Advocates for Research, Education and Science treatment on our social media pages, An initiative of the Sickle Cell Disease Association of America website and e-newsletter.

or f s e t n a e c i vo d Sc d A an f o on n the of i o t f i o ion a t C.A.R.E.S. e c a v r i at i t c a Consortiumbo Edu iti sso n a i , l l n se A h o A c r C ea ea s i s ll D e e R AND RESEARCH ADVISORY C COMMITTEE (MARAC) MEDICAL le k Sic

SCDAA’s MARAC team of acclaimed sickle cell experts monitors emerging and critical research activity, as well as clinical and treatment updates, and provides important guidance on time-sensitive topics. MARAC’s global reach helps inform sickle cell warriors, caregivers and providers across the world. Advisories were produced to respond to health news including: • Changes to Vaccine Recommendations • Executive Order for Children’s Vaccines • Response to Oxbryta® Update • Casgevy Approval for Young Children • Pociredir Program Discontinuation • L-glutamine as an Effective Therapy for Sickle Cell Disease 20 |


NATIONAL HIGHLIGHTS KEEPING SICKLE CELL DISEASE IN THE MEDIA SCDAA provided experts to national media as well as landed appearances in local and industry publications.

Dr. Edward Donnell Ivy, SCDAA chief medical officer, was asked to contribute his perspective as a warrior and physician to an article about the new standards in clinical management of cognitive care in sickle cell patients. The article was published in Healio, a healthcare industry publication for physicians and healthcare professionals. > > >

“We have known for a very, very long time that individuals with SCD are at higher risk for stroke, but we also have to keep in mind that individuals may have signs of changes without necessarily showing up on screening tests.” -Edward Donnell Ivy, MD SCDAA Chief Medical Officer

Combined national exposure through media, including affiliate pickups:

OVER 250 MILLION REACH | 21


NATIONAL HIGHLIGHTS

AWARDS AND RECOGNITIONS Outstanding Service Award In December 2025, SCDAA was humbled to accept the Outstanding Service Award alongside our colleagues at the Sickle Cell Community Consortium and Sick Cells during the American Society of Hematology’s 67th ASH Annual Meeting and Exposition. The award recognizes individuals or organizations in the public or private sector who have displayed effective behind-the-scenes leadership in areas relevant to ASH’s mission. In particular, this honor reflects the diligent work done to support ASH’s advocacy efforts, including providing feedback on policy, hosting congressional meetings and briefings on Capitol Hill and pushing for key legislation to include the Sickle Cell Disease Comprehensive Care Act. When accepting the award, SCDAA President and CEO Regina Hartfield, pictured above, paid tribute to the SCDAA staff and SCDAA’s more than 50 member organizations, noting, “It is their tireless service which underscores the need to remember that sickle cell is a disease, not a people.” Candid Gold Seal of Transparency for 2025 SCDAA is proud to have earned the 2025 Candid Gold Seal of Transparency. The Gold Seal signifies that SCDAA has provided comprehensive information about its mission, programs, finances and other key aspects of the organization, demonstrating a commitment to transparency. Less than 5% of the 1.7-million nonprofits registered with the IRS are recognized with this distinction. SCDAA Receives First Aster Award SCDAA was honored to receive a Gold Aster Award in recognition of their 2025 Annual Impact Report, Sickle Cell Strong. The award recognizes excellence in healthcare communications.

22 |


SCDAA

2026 Leadership Intensive for SCDAA Member Organizations

Wednesday, October 14 | 1 - 4 p.m. Embassy Suites by Hilton | Charlotte Concord Golf Resort & Spa | Carolina ABC Join the Sickle Cell Disease Association of America, Inc., in person the day before the 54th Annual National Convention begins for a special leadership series just for our SCDAA member organizations. Hear from our subject-matter experts on topics relevant to your organization and those you serve. Speakers and topics subject to change.

Topics include: Understanding Artificial Intelligence (AI) for Nonprofit CBOs Instructor: Rae Blaylark, President/CEO, Sickle Cell Foundation of Minnesota Beyond Government Grants: Maximizing Your Fundraising Approach Instructors: Edward Donnell Ivy, M.D., Chief Medical Officer, SCDAA; Holly John, Senior Director, Global Patient Advocacy at Agios Pharmaceuticals; and Drexel Shaw, MPH, Senior Manager, National Patient Advocacy and External Affairs Patient and Physician Advocacy at CVS Specialty. The Business of Running a Nonprofit SCD CBO: What You Need to Know Instructors: Reginald Hart, Chief Financial Officer, SCDAA; and Derek Robertson, President, Board of Directors, Maryland Sickle Cell Disease Association. Certificate of completion awarded to participants who attend all Leadership Intensive programming. Light refreshments will be provided. All members of an organization must pre-register.

Register here: bit.ly/SCDAA2026Leadership

Followed by: SCDAA Business Meeting (Member organization attendance required) 5:00-6:30 p.m. Host: Thomas Johnson, SCDAA Board Chair

SPONSORED BY:

SCDAA President’s Dinner Sponsored by Pfizer 7-9 p.m. Host: Regina Hartfield, SCDAA President and CEO

SUPPORTED BY:

® | 23


HONOR LECTURE

CHARLES F. WHITTEN, MD CHARLES F. WHITTEN, MD, was a pioneer pediatric hematologist and a

The Charles F. Whitten, MD, Memorial Lecture is given annually at SCDAA’s National Convention. Dr. Whitten was a visionary physician who transformed SCD care throughout his distinguished career. He was a relentless advocate for newborn screening for sickle cell disease, a practice that is now standard and has saved countless lives. His involvement in the research, education, clinical care, program development and advocacy of sickle cell disease has impacted care for generations. The Sickle Cell Disease Association of America, Inc., honors Dr. Whitten by honoring others, in his name, who have made significant contributions to the sickle cell community.

24 |

national leader whose vision and determination transformed SCD clinical care and policy. Dr. Whitten earned his medical degree at Meharry Medical College, and completed a residency in pediatrics at the Children’s Hospital of Buffalo and a fellowship in hematology at the Children’s Hospital of Michigan. He joined the Wayne State University (WSU) School of Medicine, initially serving as chief of pediatrics at Detroit Receiving Hospital, and had the distinction of being the first African American to head a department in a Detroit hospital. He authored over 100 journal articles and seven book chapters. In 2002, he retired with the title of Distinguished Professor of Pediatrics, Emeritus. He was one of only 15 WSU faculty who had earned that rank at the time. Because of his deep concern about the underrepresentation of African American physicians, in 1969, he launched the Post Baccalaureate Program at WSU School of Medicine, the first of its kind in the nation that offered intensive preparation, mentorship and support. During his time, WSU School of Medicine graduated more physicians of color than any other medical school except Howard University and Meharry Medical College. Dr. Whitten was instrumental in cofounding the National Association for Sickle Cell Disease, now known as the Sickle Cell Disease Association of America, Inc. In Detroit, he established the Sickle Cell Detection and Information Center. He also founded the Sickle Cell Disease Association of America, Michigan Chapter and served as its president until his death. In addition, he directed the WSU Comprehensive Sickle Cell Center Grant for 19 years, advancing both research and clinical care.


HONOR LECTURE

2026 Charles F. Whitten, MD, Memorial Lecture

Bridging the Gap: Ensuring Lifelong Access to Excellence in Sickle Cell Care Keynote Speaker: Payal Desai, MD Moderator: Wanda Whitten-Shurney, MD Thursday, October 15 | 10:30 a.m. | Concord EF

Payal C. Desai, MD, is a board‑certified hematologist and internationally recognized expert in sickle cell disease. She is an associate professor of internal medicine at Wake Forest University School of Medicine and director of the Sickle Cell Disease Enterprise at Atrium Health Levine Cancer Institute in Charlotte, North Carolina. Dr. Desai completed her hematology and oncology fellowship at the University of North Carolina at Chapel Hill and previously held progressive academic and clinical leadership roles at The Ohio State University, where she led Joint Commission certified comprehensive adult sickle cell programs and research initiatives. Dr. Desai’s work focuses on sickle cell disease and integrates clinical innovation, multicenter clinical trials, health equity and quality improvement. She has published on pain management, cardiopulmonary and renal complications, transitions of care and access to disease‑modifying and curative therapies. She has authored over 100 peer‑reviewed publications and served in multiple leadership roles within the American Society of Hematology and the Sickle Cell Adult Provider Network. Her contributions to patient care, research, mentorship and advocacy have been recognized with numerous national awards, including repeated Castle Connolly Top Doctor honors.

| 25


HONOR LECTURE

KWAKU OHENE-FREMPONG, MD KWAKU OHENE-FREMPONG, MD, was born in Ghana, and his record of

The Kwaku Ohene-Frempong, MD, Memorial Symposium is given annually at SCDAA’s National Convention.

excellence as a student-athlete earned him a scholarship to Yale to study premed and later, a trip to the Olympics representing Ghana in track and field. He received his medical degree from the Yale School of Medicine in 1975. While finishing his degree, his son became the first baby diagnosed with sickle cell disease by Dr. Howard Pearson in the pioneering newborn screening program at Yale in 1972. His firsthand experience with sickle cell and newborn testing motivated him to dedicate his life and career to studying and advocating for sickle cell.

Dr. Ohene-Frempong passed away in 2022. He was a true leader in the sickle cell community and dedicated his life and career to working with SCD.

Dr. Ohene-Frempong was director emeritus of the Comprehensive Sickle Cell Center at the Children’s Hospital of Philadelphia and professor emeritus of pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Ohene-Frempong also founded the Sickle Cell Foundation of Ghana and was a founding member of the Global Sickle Cell Disease Network.

In the United States and internationally, Dr. OheneFrempong was a leading pediatric sickle cell physician and a fierce advocate. His work changed the world for many in our community.

His landmark analysis of stroke in the Cooperative Study of Sickle Cell Disease showed the high rates of stroke in children from blocked blood flow and high rates of stroke in adults that were from bleeding aneurysms. He also pioneered a newborn screening and follow-up program in Kumasi, Ghana, where one in 50 babies have sickle cell disease.

His legacy inspires us and countless others as we push for better treatments, education and outcomes for sickle cell warriors. The Sickle Cell Disease Association of America, Inc., is proud to honor his memory by elevating the voices and efforts of those who dare to make a difference. 26 |

Dr. Ohene-Frempong held many roles on the Sickle Cell Disease Association of America, Inc., board of directors over the years, including chief medical officer, board chair and board member emeritus. He also sat on the SCDAA Medical and Research Advisory Committee.


HONOR LECTURE

2026 Kwaku Ohene-Frempong, MD, Memorial Symposium

Stroke Awareness Through the Sickle Cell Disease Lifespan Keynote Speaker: Adetola Kassim, MD Moderator: Kim Smith-Whitley, MD Thursday, October 15 | 2 p.m. | Concord EF

Adetola Kassim, MD, is a professor of medicine in the division of hematology and oncology, department of medicine at Vanderbilt University Medical Center. He is a clinical researcher in hematology and stem cell transplant and cellular therapy, focused on advancing the care and treatment outcomes for adults with sickle cell disease. Dr. Kassim is currently exploring the use of a non-myeloablative haploidentical Bone Marrow Transplant (haploBMT) as a curative modality for patients with severe SCD. He established a multicenter collaborative group in 2013, resulting in improved outcomes and increased donor options allowing for the extension of this novel curative therapy to more eligible patients with SCD in the U.S. and worldwide. The promising results from this pilot phase II trial have resulted in a National NHLBI BMT-Clinical Trial Network-supported protocol in 2017 on haploBMT in SCD. He is also a co-investigator of two NINDS funded clinical trials (SPIN and SPRING) on stroke prevention in children with sickle cell anemia in sub-Saharan Africa. SPIN is the first NIH-sponsored clinical trial on SCD in Africa, where the disease is most prevalent. He received his medical degree from the University of Lagos and completed his residency at Mount Sinai School of Medicine and multiple fellowships at Memorial Sloan Kettering Cancer Center, Yeshiva University (hematology/oncology) and The Johns Hopkins Hospital (bone marrow transplant).

| 27


HONOR LECTURE

LENNETTE BENJAMIN, MD LENNETTE BENJAMIN, MD, graduated from Denver University with a bachelor’s in chemistry followed by her medical degree from Howard University College of Medicine. She completed her internship and residency in medicine at St. Vincent’s Hospital in New York. The Lennette Benjamin, MD, Memorial Lecture is given annually at SCDAA’s National Convention. Dr. Benjamin, who passed away in 2023, was a trailblazing physician who made countless contributions to the sickle cell community. She was also a dedicated advocate and mentor who made a global impact — raising sickle cell awareness in West Africa, Brazil and beyond. Dr. Benjamin’s dedication to sickle cell disease was exemplified by her role as a board member emeritus for SCDAA and her significant contributions to the SCDAA Medical and Research Advisory Committee. The Sickle Cell Disease Association of America, Inc., is proud to honor her memory by bringing forward the voices and perspectives of those who are shaping the future of sickle cell disease. 28 |

Beginning as a research associate, she then became an adjunct faculty member in medical biochemistry and ultimately an associate physician at The Rockefeller University Hospital. Dr. Benjamin served as the associate medical director and chief of the Evaluation Unit for Emergency Medical Services at NYC Health + Hospitals Corp. and then joined the Albert Einstein College of Medicine, achieving the title of Professor of Clinical Medicine in the Department of Medicine. A prominent figure in the field of hematology, particularly in the areas of acute chest syndrome and sickle cell anemia, she authored over 200 works and was cited over 10,000 times. She was one of the first to establish a “day hospital” as an alternative to the emergency room for pain management — an approach that is recognized today as a best practice in care. Prior to her retirement, Dr. Benjamin led the Montefiore Comprehensive Adult Sickle Cell Center in the Bronx, New York. Dr. Benjamin’s accomplishments were recognized with numerous honors, including membership in Alpha Sigma Chi, Mu Beta Kappa and receiving the Fillmore Award for Post Graduate Training.


HONOR LECTURE

2026 Lennette Benjamin, MD, Memorial Lecture

Pain Management Redefined Keynote Speaker: Sophie Lanzkron, MD Thursday, October 15 | 3 p.m. | Concord EF

Sophie Lanzkron, MD, MHS, is a professor of medicine and division director of hematology at Thomas Jefferson University. She is internationally recognized for her pioneering research on the optimal care and management of patients with sickle cell disease. Dr. Lanzkron served on the National Institutes of Health Expert Panel in the Management of Sickle Cell Disease and on the American Society of Hematology (ASH) Sickle Cell Guideline Panel. She is one of the founders and currently serves as the vice president of the National Alliance of Sickle Cell Centers. She is the director of the oldest sickle cell ECHO telementoring clinic, educating over 50 clinicians each week. She was recognized by The Johns Hopkins Hospital with the Susan M. MacDonald Sponsorship Award for her sponsorship of junior faculty and fellows and was the 2025 recipient of the ASH Mentor Award in clinical science. Her research focus is on improving the quality of care provided to this historically underserved population and she is considered an expert in health services research in sickle cell disease. Dr. Lanzkron’s research is currently supported through grants from the NIH, PCORI and HRSA. She received her medical degree from Albert Einstein College of Medicine and completed a residency at the University of Maryland and a fellowship in hematology at The John Hopkins Hospital.

| 29


HONOR LECTURE

CLARICE D. REID, MD CLARICE D. REID, MD, graduated from the University of Cincinnati College of Medicine as only the third African American to earn a medical degree from the institution. After beginning her career as a pediatrician, she transitioned into federal service in the early 1970s. The Clarice D. Reid, MD, Lecture is given annually at SCDAA’s National Convention. Dr. Reid is a pioneering physician and researcher whose work and leadership at the National Institutes of Health (NIH) transformed sickle cell disease research and care. Her legacy continues to provide inspiration to countless scientists and clinicians as well community and public health practitioners. The Sickle Cell Disease Association of America, Inc., honors Dr. Reid by honoring others in her name who have made significant contributions to the sickle cell community.

In 1972, Dr. Reid joined the Sickle Cell Screening and Education Clinics within the Health Services and Mental Health Administration (HSMHA), working with the newly established Sickle Cell Screening and Education Clinics. As Deputy Director, she emphasized the importance of community programs in addressing national and local issues related to sickle cell disease and was instrumental in unifying the community service-oriented programs with the clinical and basic research programs at the NIH. The Director of the NHLBI/NIH recruited Dr. Reid to serve as Acting Chief of the Sickle Cell Disease branch. In 1976, she was appointed Chief of the Branch and the coordinator of the National Sickle Cell Disease Program. For more than twenty years, she led the national program of research and services — a role she describes as her greatest professional accomplishment. Under her leadership, landmark advances were achieved: The Cooperative Study of Sickle Cell Disease, prophylactic penicillin to prevent infections in infants, hydroxyurea to reduce painful crises in adults and universal newborn screening for sickle cell disease. Dr. Reid’s career was recognized with many honors, including the Superior Service Award from the U.S. Public Health Service and the Presidential Meritorious Executive Rank Award. She is especially proud of receiving the Assistant Secretary of Health Exceptional Service Medallion and the 2024 SCDAA Lifetime Achievement Award. Since her retirement in 1998 as director of the Division of Blood Diseases and Resources at the National Institutes of Health, Dr. Reid has continued to be a prominent figure in her community.

30 |


HONOR LECTURE

2026 Clarice D. Reid, MD, Lecture

Sickle Cell Disease: How Can Research Improve Health and Find a Cure? Keynote Speaker: Julie Makani, MD, PhD, FRCP, FTAAS Moderator: Lewis Hsu, MD, PhD Friday, October 16 | 2:05 p.m. | Concord EF

Julie Makani, MD, PhD, FRCP, FTAAS, is a physician scientist in the Department of Haematology and Blood Transfusion in Tanzania at Muhimbili University of Health and Allied Sciences (MUHAS) and Principal Investigator at the MUHAS Sickle Cell Centre and SickleInAfrica Clinical Coordinating Centre. She is a visiting professor at Imperial College in the Department of Immunology and Inflammation in London and Science Advisor at the Tanzania High Commission in the UK and the East, Central and Southern Africa Health Community. Her work aims to use sickle cell disease as a model to establish scientific and healthcare solutions in Africa that are locally relevant and globally significant. The approach integrates public health interventions with genomics including gene therapy to improve health and cure sickle cell disease. Professor Makani trained in medicine in Tanzania and specialized in internal medicine and completed her PhD in clinical epidemiology of sickle cell disease in the UK. She received the 2011 Royal Society Africa Award on the application of genomic research to improve health and find a cure for sickle cell disease. She is a Fellow of the Royal College of Physicians, Wellcome Trust Research, Tutu Leadership and Tanzania Academy of Sciences and was an Honorary Visiting Research Fellow at the University of Oxford.

| 31


ADVOCACY UPDATE National Sickle Cell Disease Advocacy Update

The Current State of Sickle Cell Disease in Today’s Federal Government Keynote Speaker: Georges C. Benjamin, MD, MACP, FACEP (E), FNAPA, Hon FFPH, Hon FRSPH Moderator: Thomas L. Johnson, JD Thursday, October 15 | 1 p.m. | Concord EF Georges C. Benjamin, MD, is the chief executive officer of the American Public Health Association. Since 2002, he has been leading the Association’s push to make America the healthiest nation. Previously, he served as secretary of the Maryland Department of Health and Mental Hygiene and oversaw the expansion and improvement of the state’s Medicaid program. Dr. Benjamin is a graduate of the Illinois Institute of Technology and the University of Illinois College of Medicine. Dr. Benjamin started his medical career in 1978 as a military physician with the U.S. Army. He has combined his practice and academic experience as an emergency physician with public health to become one of the nation’s experts in public health emergency preparedness. He is board certified in internal medicine and a master of the American College of Physicians, a fellow of the National Academy of Public Administration, a fellow emeritus of the American College of Emergency Physicians, an honorary fellow of the Faculty of Public Health and an honorary fellow of the Royal Society of Public Health. He is the author of more than 200 scientific articles and book chapters. His recent book, “Public Health Under Siege: Improving Policy in Turbulent Times,” explores the impact of policy on our nation’s health and offers specific actions to improve health and extend life expectancy. In 2008, 2014 and 2016, he was named one of the top 25 minority executives in healthcare by Modern Healthcare Magazine, in addition to being voted among the 100 most influential people in healthcare from 2007-2018 and in 2021-2025. In 2023-2025, Washingtonian Magazine voted Dr. Benjamin one of the 500 most influential people shaping policy. 32 |


HONOR LECTURE Global Perspectives on Sickle Cell Disease

Perspectives on Sickle Cell Disease in Sub-Saharan Africa Keynote Speaker: Isaac Odame, MB ChB, MRCP (UK), FRCPath, FRCPC Friday, October 16 | 1:15 p.m. | Concord EF

Isaac Odame, MD, serves as head of the hematology section and director of the hemoglobinopathy program within the division of hematology/oncology at the Hospital for Sick Children (SickKids) in Toronto, Ontario. He is also medical director of the Global Sickle Cell Disease Network at the SickKids Centre for Global Child Health. In these capacities, he cultivates enduring collaborations among clinicians and researchers worldwide to advance scientific knowledge and strengthen care for sickle cell disease (SCD), particularly in low- and middle-income countries, where the burden remains greatest. Dr. Odame is a professor in the departments of pediatrics and medicine at the Temerty Faculty of Medicine, University of Toronto. From 2013 to 2024, he served as division director and Alexandra Yeo Chair of Hematology at the University of Toronto. He also chairs the World Coalition on Sickle Cell Disease (WCSCD), an international public-private partnership dedicated to mobilizing cross-sector investment and coordinated action to address SCD in low- and middle-income countries. In addition, he leads implementation studies focused on integrating early SCD diagnosis and management into primary healthcare centers across sub-Saharan Africa. As a site principal investigator and a member of multiple steering committees and data safety monitoring boards, he remains actively engaged in clinical trials evaluating novel disease-modifying and curative therapies for SCD. Dr. Odame also serves as an associate editor for Pediatric Blood & Cancer and as a member of the Editorial Advisory Board of The Lancet Child & Adolescent Health.

| 33


SUMMIT 2026

Summit on Stem Cell Transplant and Cellular Therapies: Where Are We Now? Sponsored by: ®

Moderator: Crawford J. Strunk, MD Friday, October 16 | 9 a.m. | Concord EF Topics and Presenters: State of the State: Advances in Bone Marrow Transplantation

Adetola Kassim, MD, is a professor of medicine in the division of hematology and oncology, department of medicine at Vanderbilt University Medical Center. He is a clinical researcher in hematology and stem cell transplant and cellular therapy, focused on advancing the care and treatment outcomes for adults with sickle cell disease.

State of the State: Advances in Cell and Gene Therapy

Michael Kent, MD, is the assistant professor of pediatrics and the processing lead for the Atrium Health Pediatric Stem Cell Transplant team at Levine Children’s Cancer & Blood Disorders, a facility of Carolinas Medical Center. He specializes in treating children with sickle cell anemia, including the use of stem cell transplants and gene therapies.

Survivorship: CBOs, Mental Health, Identity

Andrew Campbell, MD, is the director of the Comprehensive Sickle Cell Disease Program at Children’s National in Washington, DC. Previously, Dr. Campbell was director of the Comprehensive Sickle Cell Center at the University of Michigan. His sickle cell disease research interests include pulmonary complications, fetal hemoglobin switching in transgenic sickle cell mice, phenotype/ genotype relationships and renal complications.

Future State: Cell and Gene Therapy — Tomorrow and Beyond Panel Discussion 34 |


PATIENT EMPOWERMENT SYMPOSIUM

Don’t Get Duped Because It’s Called BUP! Moderator: Genice T. Nelson, DNP, APRN, ANP-BC Friday, October 16 | 11 a.m. | Concord EF Presenter:

Megan Mitchell, PharmD, is the pharmacy clinical coordinator for pain management and palliative care at the UConn Health Center. She completed a specialty residency in pain management and palliative care, an interdisciplinary pain and palliative care fellowship, and a Master of Science degree in palliative care at the University of Maryland, Baltimore.

S I C K L E

C E L L

D I S E A S E

A S S O C I AT I O N

O F

A M E R I C A ,

I N C .

®

Thanks to all of the convention speakers for your support of our 54TH ANNUAL NATIONAL CONVENTION! | 35


Sickle Cell Disease Association of America, Inc. presents the ®

2026 Masterclass Series

PART TWO:

CHRONIC or ACUTE?

Rethinking the Approach to Sickle Cell Disease Care Saturday, October 17 | 10:15 a.m. | Concord EF Expert-Led Discussion and New Perspectives

Join us as our panel of experts and warriors explore how new approaches in sickle cell disease care can help improve outcomes and shape how healthcare is addressed now and in the future.

Panelists: Edward Donnell Ivy, MD, MPH Crawford J. Strunk, MD

Moderator: Wally R. Smith, MD

Legacy Sponsor

36 |

Visionary Sponsor


bluebird bio is now GENETIX BIOTHERAPEUTICS We are honored to join the Sickle Cell Disease Association of America, Inc. (SCDAA) in its mission to advocate for people affected by sickle cell conditions and advance the search for a universal cure, and look forward to seeing you at our table at SCDAA’s Annual National Convention from October 15–17.

Our name has changed, but our mission remains the same–transforming lives through curative therapies for people with sickle cell disease.

Scan here to visit genetixbiotx.com

© 2026 Genetix Biotherapeutics Inc. All rights reserved. Corp-US-00262 04/26

Knowing your sickle cell trait status matters CVS Specialty® can help you prepare and connect to resources

| 37


2026

AWARD WINNERS 2026 CHAIRMAN AWARD Honors a dedicated leader in the sickle cell community whose exceptional service has uplifted sickle cell warriors and caregivers. This recognition highlights individuals whose tireless service and commitment have strengthened SCDAA’s mission and created a lasting impact on the sickle cell community. Congressman Glenn F. Ivey Congressman Glenn F. Ivey (D-MD) was elected in 2022 to represent Maryland’s 4th Congressional District. He serves on the House Appropriations Committee, including the Commerce, Justice, Science and Financial Services and General Government Subcommittees, as well as the House Ethics Committee. A former prosecutor, he focuses his work on protecting the rule of law, supporting federal workers, advancing public safety and policing reform and expanding economic opportunities for working families. He graduated with honors from Princeton University and earned his law degree from Harvard Law School. Congressman Richard McCormick Congressman Richard McCormick (D-GA) is a decorated veteran and physician who serves Georgia’s 7th Congressional District. During his two decades of service in the Marine Corps, Dr. McCormick was deployed to combat zones and served as a helicopter pilot. He earned his Master of Business Administration from National University and medical degree from Morehouse School of Medicine. He completed a residency in emergency medicine through Emory while training at Grady Hospital in Atlanta, Georgia. Most recently, Dr. McCormick served as an emergency room physician. In Congress, Dr. McCormick serves on the House Armed Services, House Oversight and Science, Space and Technology committees.

2026 PRESIDENT’S AWARD Honors an SCD leader whose vision, dedication and leadership have driven significant progress for the sickle cell community. The award recognizes an individual who has led their organization to launch innovative initiatives or achieve remarkable accomplishments that have created meaningful and lasting impact on warriors and caregivers. Their passion and commitment have set a standard of excellence for advancing sickle cell advocacy, support and awareness. Wally R. Smith, MD Dr. Wally R. Smith is the Florence Neal Cooper Smith Professor of Sickle Cell Disease at Virginia Commonwealth University (VCU). He also serves as the vice chairman for research of the Division of General Internal Medicine and is the former Scientific Director of the Center on Health Disparities at VCU. Dr. Smith is an experienced implementation scientist and an expert in clinical and health services research in sickle cell disease. He has authored over 100 publications and served as an investigator on over 50 externally funded grants and contracts. Dr. Smith has been associated with the development of two potential lead compounds for sickle cell disease at VCU. 38 |


2026 COMMUNITY HEALTH WORKER P.O.W.E.R. AWARD Celebrates an exceptional community health worker (CHW) who embodies professionalism, integrity and dedication in serving the sickle cell disease community. This honor recognizes a CHW who consistently goes above and beyond to provide support, advocacy and empowerment, making a meaningful difference in the lives they touch. Their work reflects the highest values of the profession and a deep commitment to improving health outcomes. Cathy McCoy, CHW Cathy McCoy has made a significant and meaningful difference in the lives of individuals and families affected by sickle cell disease. Through her tireless advocacy, patient-centered approach and commitment to improving health outcomes, she has become a trusted resource and steadfast supporter for countless members of the SCD community. Her ability to build impactful relationships with patients, caregivers, healthcare providers and community partners has strengthened access to care while fostering trust, education and empowerment. Cathy’s leadership has strengthened communication, enhanced community participation, and fostered an environment where individuals affected by sickle cell disease feel heard, valued and supported. She continually seeks innovative ways to educate individuals, promote disease awareness and empower patients to become active participants in their healthcare.

2026 ADVOCACY AWARD Recognizes an individual who has gone above and beyond in championing the needs of the sickle cell community and amplifying their voice through passionate and persistent action. This individual has made it their mission to raise awareness, influence meaningful change and create a lasting positive impact on those living with sickle cell disease, their caregivers and the entire sickle cell community. Their tireless dedication and unwavering commitment embody the true spirit of advocacy. Velvet L. Brown-Watts, MSW-ADM, CM, CHC Velvet L. Brown-Watts is a pioneering social worker and community advocate whose journey of advocacy began with the diagnosis of her son with SCD. Velvet is the founder and chairperson of Supporters of Families with Sickle Cell Disease, Inc. (SFSCD), an Oklahoma nonprofit organization serving families affected by sickle cell and related hemoglobin disorders and traits. For nearly two decades, Velvet has worked to bring the voices and experiences of individuals and families living with sickle cell disease into spaces where decisions about their lives and care are made. She has also contributed to statewide efforts to identify gaps in sickle cell services and elevate patient- and family-centered recommendations for improving care.

| 39


2026

AWARD WINNERS 2026 CHAMPION AWARD Honors an individual who has demonstrated exceptional dedication to advancing the cause of sickle cell disease through leadership, advocacy and/or action. This award recognizes a staunch supporter — often a legislator or influential leader — who has championed legislation, policy or funding to improve the lives of those affected. Their tireless efforts and unwavering commitment have made a lasting impact on the sickle cell community. Jimi Olaghere Jimi Olaghere lived with the limitations, pain and frequent hospitalizations that come with SCD for over three decades before successfully undergoing gene therapy through a clinical trial. The therapy was lifechanging “breaking the chain of SCD,” as Jimi describes it, that was holding him back from living life. He took his journey to new heights after receiving gene therapy, becoming the first person with SCD to summit Mt. Kilimanjaro. Today, he is an SCD advocate and is passionate about educating warriors on clinical trials and the positive impact these therapies can have on patients in need. He has become a staunch advocate for increased accessibility of gene therapies for SCD patients worldwide. State Senator Gladys A. Robinson North Carolina District 28 State Senator Gladys A. Robinson’s career spans more than two decades. Her efforts have earned her recognition as a staunch defender of education. She also has a passion for healthcare and believes all North Carolinians have a right to have access to affordable and quality healthcare. She has championed legislation to expand Medicaid and has been an avid champion for sickle cell disease, securing funding and legislation that have worked to raise awareness and gather resources to ensure the use of cutting-edge medical technology when combatting this disease. Senator Robinson is also an appointed member of the Governor’s Advisory Council on sickle cell disease. State Representative Terry M. Brown Jr. Terry M. Brown Jr. represents North Carolina’s 92nd House District and serves as Chief Democratic Whip in the North Carolina House of Representatives. Representative Brown is also a member of the North Carolina Council on Developmental Disabilities and serves on the Governor’s Appointed Council on Sickle Cell, where he has worked to advance awareness, treatment access and support for individuals and families living with sickle cell disease. His broader legislative record reflects a commitment to public health and vulnerable communities: during the 2025-2026 biennium he was the primary sponsor of House Bill 633 to Expand Sickle Cell Disease Programs and Services, a portion of which was included in the 2026 state budget providing over $1 million to quality care and services to those affected by sickle cell in North Carolina.

40 |


2026 LIFETIME ACHIEVEMENT AWARD Honors an individual whose lifelong dedication, passion and body of work has significantly advanced the sickle cell community. Through both their professional and personal efforts, they have championed positive change, increased awareness and improved the lives of those living with sickle cell disease and their caregivers. Through their life’s work, they have made a profound impact on the community, creating a lasting legacy of dedication, progress and hope for future generations. Lewis Hsu, MD, PhD Lewis Hsu, MD, PhD, is a professor of Pediatric Hematology-Oncology and the director of the Pediatric Sickle Cell Center at University of Illinois Chicago (UIC). Over a career spanning more than 30 years, he has served as a physician, researcher, educator and advocate dedicated to improving the lives of individuals with SCD. Dr. Hsu has led pediatric sickle cell centers at Emory University, St. Christopher’s Hospital for Children, Children’s National Hospital and now UIC. His research contributions include landmark team studies in sickle cell stroke prevention and bone marrow transplantation, with more than 130 scientific publications. His current work focuses on improving access to SCD therapies using implementation science, CHWa and global partnerships in Nigeria and Brazil. Dr. Hsu has global experience developing health education materials to include books, websites, videos, conferences and health fairs to empower families to overcome the complex problems of SCD. A longtime volunteer for SCDAA, Dr. Hsu has served as vice chief medical officer and chief medical officer and continues to serve as a member of the SCDAA Board of Directors. He helped lead SCDAA’s national education campaigns on COVID-19, COVID vaccination and gene therapy for SCD.

2026 ICON AWARD Created to acknowledge an individual(s) who, by philosophy, actions and/or deeds significantly impacts the sickle cell disease community or landscape. This is not an annual award, but one that will be given from time to time to an individual who displays exemplary service to the SCD community, is deeply respected and admired and has a lasting and significant influence on the sickle cell community regionally, nationally or globally. Annie J. Ross-Womack Annie J. Ross-Womack, the first Icon Award recipient, exemplifies the attributes of this award through her deep commitment to the cause, people, rights and policies, and to what is fair and equitable; and who serves with compassion and purpose—setting the bar for those she touches and beyond. Annie serves as the executive director of the Sickle Cell Disease Association of America/Ohio Sickle Cell and Health Association, Inc. Beyond her executive leadership, Annie is a fierce voice at decision-making tables, serving on numerous boards and councils that shape policy and equity. Because of leaders like Annie, advocacy is strengthened, communities are rebuilt, and warriors have a champion in every room. | 41


THANK YOU SCD C.A.R.E.S. Consortium Members

The SCD C.A.R.E.S. (Collaboration of Advocates for Research, Education and Science) Consortium raises awareness about the importance of clinical trials and why it’s beneficial for sickle cell warriors to participate in them. Sickle Cell Disease Association of America, Inc., along with our strategic partners, joined together to educate and encourage more trial participation while providing opportunities and therefore better options for the treatment of sickle cell disease. Learn more at sicklecelldisease.org/CARES-Consortium.

Join the SCD C.A.R.E.S. Consortium Session:

PIPELINE NEWS

FRIDAY, OCTOBER 16 | 3 P.M. | CONCORD EF

42 |


SCDAA MEMBERS ALABAMA • North Alabama Sickle Cell Foundation – Huntsville • SCDAA – West Alabama Chapter – Northport • SCDAA – Central Alabama – Birmingham • SCDAA – Mobile Chapter Inc. – Mobile • Sickle Cell Foundation of the River Region – Montgomery • Southeast Alabama Sickle Cell Association Inc. – Tuskegee CALIFORNIA • Cayenne Wellness Center – Glendale COLORADO • Colorado Sickle Cell Association Inc. – Denver CONNECTICUT • SCDAA Connecticut – New Haven DELAWARE • Tova Community Health – Wilmington FLORIDA • Levi Long Sickle Cell Association Inc. – Daytona Beach • SCDAA – Miami-Dade County Chapter Inc. – Miami • SCDAA – Escambia and Santa Rosa Counties – Pensacola • SCDAA – St. Petersburg Chapter – St. Petersburg • Sickle Cell Disease Association of Broward County – Fort Lauderdale • Sickle Cell Disease Association of Florida – Tampa • Sickle Cell Foundation Inc. – Tallahassee • Sickle Cell Foundation of Palm Beach County & Treasure Coast – West Palm Beach • Sickle Cell Medical Advocacy Inc. – Orlando • Tri-County Sickle Cell Disease Association – Orlando GEORGIA • Sickle Cell Foundation of Georgia Inc. – Atlanta ILLINOIS • Sickle Cell Disease Association of Illinois – Chicago • Sick Cells – Wheaton INDIANA • Martin Center Sickle Cell Initiative – Indianapolis | 43


SCDAA MEMBERS KANSAS • Uriel E. Owens Sickle Cell Disease Association of the Midwest – Kansas City KENTUCKY • Sickle Cell Association of Kentuckiana – Louisville LOUISIANA • Etta Pete Sickle Cell Anemia Foundation – Lake Charles • Northeast Louisiana Sickle Cell Anemia Foundation Inc. – Monroe • Sickle Cell Anemia Resource Foundation – Alexandria • Sickle Cell Association of South Louisiana – Baton Rogue • Sickle Cell Disease Northwest Louisiana – Shreveport MARYLAND • Association for the Prevention of Sickle Cell Anemia Inc. – Harford/Cecil Counties and Eastern Shore – Aberdeen • Maryland Sickle Cell Disease Association – Columbia MASSACHUSETTS • Massachusetts Sickle Cell Association – Boston MICHIGAN • SCDAA – Michigan Chapter Inc. – Detroit MINNESOTA • Sickle Cell Foundation of Minnesota – Minneapolis MISSOURI • Sckle Cell Association of St. Louis – St. Louis NEVADA • Bridging the Gap Adult Sickle Cell Foundation of Nevada – Las Vegas NEW JERSEY • The Sickle Cell Association of New Jersey Inc. – Newark NEW MEXICO • The Sickle Cell Council of New Mexico Inc. – Albuquerque NEW YORK • Candice’s Sickle Cell Fund, Inc. - New York • Falling Angels Sickle Cell Foundation – Garnerville 44 |


SCDAA MEMBERS NORTH CAROLINA • Bridges Pointe Sickle Cell Foundation – Durham • Piedmont Health Services and Sickle Cell Agency – Greensboro OHIO • SCDAA/Ohio Sickle Cell and Health Association – Columbus OKLAHOMA • Supporters of Families with Sickle Cell Disease Inc. – Tulsa OREGON • Sickle Cell Anemia Foundation of Oregon – Portland PENNSYLVANIA • Children’s Sickle Cell Foundation Inc. – Pittsburgh • SCDAA – Philadelphia/Delaware Valley Chapter – Philadelphia SOUTH CAROLINA • James R. Clark Memorial Sickle Cell Foundation – Columbia • Louvenia D. Barksdale Sickle Cell Anemia Foundation – Spartanburg • The Riley Foundation for Sickle Cell Disease – Little River TENNESSEE • Sickle Cell Foundation of Tennessee – Memphis TEXAS • Sickle Cell Association of Houston – Houston • Sickle Cell Association of Texas Marc Thomas Foundation – Austin VIRGINIA • Sickle Cell Association Inc. – Norfolk WISCONSIN • Sickle Cell Warriors of Wisconsin – Milwaukee

| 45


PROUD GOLD SPONSOR

46 |


CLINICAL TRIAL FINDER

SEARCH WEBSITE + CONNECT TO CLINICAL TRIALS

The Sickle Cell Disease Association of America, Inc., Clinical Trial Finder is a centralized, simple-to-navigate resource that helps people with sickle cell disease, their families and caregivers find clinical trials. Your participation helps guide breakthroughs and also gives you access to new treatments before they are available to the public. You are our heroes! Search for trials by keyword, location, study type and phase — all in one place. Download from the Apple or Android app store today of visit us online!

bit.ly/SCDAA-Trial-Finder

® | 47


THANK YOU TO

OUR SPONSORS LEGACY

VISIONARY

DIAMOND

PLATINUM

48 |


GOLD

SILVER

BRONZE

®

SUPPORTER

| 49


WAYS TO GIVE SUPPORT

NON-CASH

Together, we can make a difference in the lives of those who are affected by sickle cell disease! Your tax-deductible donation to SCDAA will assist us in providing critical support to our chapters and affiliates throughout the country. Please consider a gift today.

SCDAA accepts the gift of non-cash assets such as stock, charitable IRA distributions or cryptocurrency. Contact Reginald Hart, Jr., at rphartjr@sicklecelldisease.org or call 410-528-1555.

OUR COMMUNITY

WORKPLACE GIVING CAMPAIGNS

Support SCDAA through your company’s annual corporate giving campaign. It is a convenient way to give through regular payroll deductions. SCDAA participates in the Community Health Charities Federation, the largest workplace giving campaign devoted to health. If your employer participates in Community Health Charities campaigns, designate your contribution to Sickle Cell Disease Association of America, Inc. SCDAA also accepts matching gifts. For more information, contact Erika Cartledge at ecartledge@sicklecelldisease.org or call 410-528-1555.

GIFTS

LEGACY DONATION

A planned gift is a contribution that requires planning and offers opportunities for you to support SCDAA now and in the future. Remembering SCDAA gives you the opportunity to leave a legacy in support of our mission. Consider a bequest, charitable annuity or other option. For more information on how to leave a legacy donation, please contact Reginald Hart, Jr., at rphartjr@sicklecelldisease.org or call 410-528-1555.

DONATE TODAY

TRIBUTE MEMORIAL

Make a donation in honor of a loved one. Create a personal page with a picture of your loved one and invite friends and family to donate in memory or in honor of the person.

SCDAA | 7240 PARKWAY DRIVE, SUITE 180 | HANOVER, MD 21076 | SICKLECELLDISEASE.ORG 50 |


Every patient story shapes our science. The sickle cell community has a voice, and we’re listening. Because your stories fuel our mission to develop and deliver medicines with the potential to transform lives. Visit our booth to learn how we’re taking on sickle cell disease.

Some patients featured were compensated for their time.

| 51


Novo Nordisk is committed to building a future where people with sickle cell disease can live unlimited!

To learn more, please visit our website liveunlimited.com or scan the QR code. No data will be collected by scanning.

Novo is a registered trademark of Novo Nordisk A/S. © 2026 Novo Nordisk Printed in the U.S.A. US26SCD00249 October 2026

Stay connected by following us on @liveunlimitedscd.


Turn static files into dynamic content formats.

Create a flipbook